Illumina Inc

Research Illumina Inc (ILMN) on Bullrun: valuation model: 7.5% undervalued, market cap USD 27.40B, P/E 32.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerILMN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyUSD
• Valuation signal7.5% undervalued
• Market capUSD 27.40B
• P/E32.9
• Financial periodFY2025
• RevenueUSD 4.34B
• Revenue growth-0.7%
• Net incomeUSD 850.00M
• Free cash flowUSD 931.00M
• Gross margin66.1%

Valuation Snapshot

Bullrun's latest valuation model marks Illumina Inc as 7.5% undervalued; latest market cap is USD 27.40B; P/E is 32.9.

About Illumina Inc

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity;

Frequently asked questions

Is Illumina Inc overvalued or undervalued?

Bullrun's valuation model currently marks Illumina Inc as 7.5% undervalued.

What is Illumina Inc's market cap?

Illumina Inc's market capitalization is USD 27.40B.

What is Illumina Inc's P/E ratio?

Illumina Inc's price-to-earnings (P/E) ratio is 32.9.

What does Illumina Inc do?

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.